Form 4 for DXCM Dexcom

Accepted 2025-01-30 00:00:00 ET · period of report 2025-01-28 · accession 0001093557-25-000015 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
	2025-01-30	2025-01-28	DXCM	SAYER KEVIN R	COB, CEO, Pres, Dir	A - Grant	$0.00	+68.5K	352.4K	+24%	$0
	2025-01-30	2025-01-29	DXCM	SAYER KEVIN R	COB, CEO, Pres, Dir	S - Sale	$86.91	-33.4K	319.0K	-9%	-$2.90M

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2025-01-28	A	A	68,503	$0.00	352,396	D	—	—	(F1) Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2022 that vested on January 28, 2025. (F2) Included in this number are 109,641 unvested restricted stock units, 51,692 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 36,281 of which were granted on March 9, 2023 and shall vest through March 8, 2026, and 21,668 of which were granted on March 8, 2022 and shall vest through March 8, 2025.
2	Common	Common Stock	2025-01-29	S	D	33,359	$86.91	319,037	D	—	—	(F3) Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of PSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. (F2) Included in this number are 109,641 unvested restricted stock units, 51,692 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 36,281 of which were granted on March 9, 2023 and shall vest through March 8, 2026, and 21,668 of which were granted on March 8, 2022 and shall vest through March 8, 2025.